Introduction
HLA class I molecules, particularly HLA-C alleles and those sharing a Bw4 epitope, modulate graft-vs-malignancy effects following hematopoietic SCT (HSCT) by acting as ligands to inhibitory killer Ig-like receptors (KIRs). HLA-C alleles are grouped according to the amino acid in position 80 as either HLA-C Asn80 (HLA-C group 1, subsequently termed C1), which are ligands for the inhibitory KIR2DL2/3, or HLA-C Lys80 (HLA-C group 2, or C2), which bind to the inhibitory KIR2DL1. Thus, C1 homozygous (C1/1) individuals lack a ligand for KIR2DL1 and C2/2 individuals lack a ligand for KIR2DL2/3, while C1/2 individuals possess ligands for both KIR2DL1 and KIR2DL2/3. Bw4, but not Bw6 epitopes, serve as ligands for the inhibitory KIR3DL1. Several studies have suggested that a graft-vs-host (GVH)-directed KIR ligand mismatch according to the ligand-ligand model may augment graft-vs-malignancy, and hence improve PFS following class I mismatched unrelated or haploidentical transplantation. [1] [2] [3] [4] [5] [6] However, others did not reproduce this observation. [7] [8] [9] [10] Even more controversial is the missing KIR ligand model, a simplified version of the receptor-ligand model. These models are independent of an HLA mismatch, that is, natural killer (NK) alloreactivity is assumed if the recipient lacks the HLA ligand to one or more of the donor's (actual or presumed) inhibitory KIR, irrespective of the donor's HLA KIR ligand status. As most Caucasians possess a full complement of inhibitory KIRs, 11 the missing KIR ligand model has been suggested an acceptable surrogate for the receptor-ligand model, having the advantage that donor KIR typing is not required. 3, [12] [13] [14] In this way, a series of studies have addressed the role of missing KIR ligands in HSCT, but reached partly divergent results. Several studies were compatible with the missing KIR ligand model. 3, 5, [15] [16] [17] [18] However, others did not reveal a benefit of missing KIR ligands, 13, 19, 20 or even showed an adverse effect, particularly in C2/2 recipients. 12, 14, 21, 22 In T cell replete, non-antithymocyte globulin (ATG)-based sibling PBSCT, we have recently reported a superior OS and PFS in C1/2 heterozygous recipients compared with C2/2 recipients, 21 a finding diametrically opposed to the missing KIR ligand model. As previous studies supporting the missing KIR ligand model were mostly based on BMT, we have previously formulated the hypothesis that a benefit of missing KIR ligands may exist in BMT while lacking in T cell replete PBSCT. 21 To our knowledge, this issue has not been addressed as a primary endpoint as yet. Further, it is generally accepted that T cell depletion or CD34 þ selection of the graft (summarized as T cell depletion (TCD)) is a prerequisite for a benefit of both KIR ligand mismatch and missing KIR ligands. However, the role for in vivo TCD by ATG has not yet been systematically investigated.
Therefore, the primary endpoint of this retrospective study was to test our previous hypothesis that missing KIR ligands have differential effects on PFS in BMT vs PBSCT, and/or in ATG-based vs non-ATG-based HSCT. In addition, we aimed to determine whether such putative differences might translate into an advantage for a specific treatment in subgroups defined by KIR ligand status.
Patients and methods

Data collection
We retrospectively evaluated 382 HSCT (118 BMT and 264 G-CSF-mobilized PBSCT), performed between November 1988 and March 2010 at the Stem Cell Transplantation Unit of the Innsbruck Medical University. Transplants meeting the following criteria were included (see also Table 1) : first (n ¼ 362) and second (n ¼ 20) allogeneic, but no subsequent allotransplants, for recipients older than 17 years; patients with previous single or double autologous transplants (n ¼ 20) were included; the donor was a matched sibling (haploidentical transplants were not included) or an unrelated donor with a maximum of two identified Ag or allele mismatches; availability of HLA-C typing at low or high resolution. A small proportion of patients, that is, those who succumbed to a pre-existing condition (for example, neutropenic infection and uncontrolled malignancy) before engraftment and earlier than In vivo T cell depletion was predominantly achieved by pretreatment with low-dose (5 mg/kg) thymoglobulin, as described previously 24 . g In two cases, tacrolimus was substituted for CsA. h Acute leukemia in 1st CR, CML in 1st CP, and non-malignant disease (for example, severe aplastic anemia, paroxysmal nocturnal haemoglobinuria) were considered standard risk. All other indications were rated high risk. day þ 14 post HSCT (n ¼ 10), were excluded because they did not contribute to the study's issue. Ten transplants had to be omitted because of missing information on HLA-C. According to the rules of the local ethics committee, the Declaration of Helsinki, and EBMT practice, patients gave written informed consent before any diagnostic or treatment procedure, and agreed to anonymized handling of clinical data for research purposes.
Treatment details
Treatment characteristics are summarized in Table 1 . Briefly, standard myeloablative conditioning (see Table 1 ) was given to patients with leukemia considered eligible for this treatment. Two conditioning regimens for patients with myeloma or lymphoma were additionally assigned to the myeloablative regimens, that is, high-dose BU combined with melphalan 140 mg/sqm body surface area and the high-dose CBV protocol 23 ( Table 1) . Patients ineligible for standard intensity conditioning received less-toxic preparative regimens, comprising reduced-intensity conditioning (RIC) and truly non-myeloablative (NMA) regimens (Table 1) . GVHD prophylaxis consisted of trough level-adjusted CYA, mostly in combination with either short-course MTX (15 mg/sqm on d1, followed by 10 mg/sqm on d3, d6 and d11, predominantly following standard myeloablative transplants), or in combination with mycophenolate mofetil (1000 mg twice daily for at least 28 days; predominantly following RIC or NMA transplants). Prophylactic in vivo TCD was applied for the majority of unrelated transplants performed in CR, mainly using lowdose (5 mg/kg) rabbit ATG (Thymoglobulin, Genzyme Austria, Vienna, Austria) during the conditioning phase, as described previously. 24 Standard anti-infective prophylaxes included trimethoprim-sulfamethoxazole for at least 6 months, acyclovir or valacyclovir for at least 6-12 months and primary antifungal prophylaxis with fluconazole or, more recently, with posaconazole in case of active GVHD. The standard anti-CMV strategy comprised the preemptive use of ganciclovir or valganciclovir, based on regularly performed antigenemia tests. Until 1995, HLA typing was performed for HLA class I and II using serological methods. From 1996 to present, PCR amplification methods with sequence-specific primers were used for HLA class II typing. Molecular HLA class I typing was performed if serological typing showed ambiguous results. High-resolution typing for HLA-C was available in 49 transplants (12.8% of the cohort).
Statistical analysis
Data were analyzed as of 1 June 2010. Statistical analyses were performed using NCSS 2001 software (NCSS, Kaysville, UT, USA). For univariate analyses, KaplanMeier survival analysis was performed for OS and PFS. Cumulative incidence analyses (considering competing risks) were applied to calculate the risks for relapse/ progression and non-relapse mortality (NRM). OS was defined as the time from HSCT to death from any cause, PFS as the time from HSCT to relapse (in the case of leukemia) or progression (if no CR was achieved, for example, in the case of myeloma), or death. In nonmalignant disease (for example, severe aplastic anemia), secondary graft rejection was rated as relapse. All deaths in continuous remission of the underlying disease were declared as NRM. Curves were compared using the logrank test. Multivariate Cox regression analysis was calculated for the probabilities for OS (with the risk ratio (RR) referring to death), PFS (with the RR referring to death or relapse/progression), relapse/progression and NRM. The following variables have been included in the model. Continuous variables: patient age, donor age and chronological order of the transplant, accounting for the year of transplant. Categorical variables (in brackets: the respective prevalence in the entire cohort, if not stated in Table 1 ): HLA-C KIR ligand status of the recipient: C1/1 (39) vs C1/2 (43) vs C2/2 (18%); missing HLA-Bw4 (that is, Bw6 homozygosity, 28%); graft type (BM vs peripheral blood), TCD (yes/no), regimen intensity (standard vs RIC/ NMA), application of full-dose (12 Gy) fractionated total body irradiation (yes/no), recipient-donor relationship (sibling vs unrelated), HLA match (well matched vs partially matched or mismatched), AB0 match (major incompatibility, 28%; minor incompatibility, 27%), CMV serology of patient (66% positive) and donor (52% positive), disease risk category (as defined in Table 1 ) and sex match (female donor to male recipient, 26%, vs all other). Variables without significant impact were eliminated stepwise, until only those variables with a P-value p0.1 remained in the model. In contrast, established risk factors, that is, age and disease stage, remained in the model irrespective of their significance within the analyzed subgroup. All probabilities for OS, PFS, relapse or NRM indicated in the text refer to 4 years after HSCT.
Results
Adverse impact of C2 group homozygosity in PBSCT but not in BMT In the combined analysis of BMT and PBSCT (entire cohort, n ¼ 382), neither the HLA-C KIR ligand status nor the absence of HLA-Bw4 influenced any of the addressed endpoints. However, the separate analysis of PBSCT (n ¼ 264) confirmed our previous finding of a reduced relapse risk for C1/2 heterozygous compared with C1 or C2 homozygous recipients. Particularly, this analysis revealed C2 homozygosity of the recipient as an adverse factor for OS, PFS and relapse incidence, both by univariate and by multivariate analysis (Table 2 ). Even after correction for multiple testing (Bonferroni's method, considering three separate tests, that is, for the effect of C1/1, C1/2 and C2/2), the deleterious effect of C2 homozygosity on PFS and relapse incidence in PBSCT remained significant (Table 2) . These findings in PBSCT clearly contrast with the missing KIR ligand model. On the contrary, following BMT (n ¼ 118), C2 homozygous recipients had favorable OS, PFS and relapse risk, particularly in comparison with C1/2 heterozygous recipients, who had an increased relapse risk after BMT (Table 2) . Of note, the findings in BMT are in accordance with the missing KIR ligand model. Together, the opposing effects of HLA-C KIR ligands in BMT vs PBSCT support the hypothesis addressed by the study's primary endpoint.
Bone marrow as the favorable graft source for C2 homozygous recipients The above findings raised the question whether BMT might compare favorably to PBSCT as transplant type for C2/2 recipients. Therefore, the cohort was grouped according to the HLA-C KIR ligand status for separate analysis of the influence of the graft source. The most significant effect of the graft source was indeed observed in C2/2 recipients (n ¼ 68). Here, BMT was significantly superior to PBSCT regarding OS and PFS, both by univariate and multivariate analysis (Figures 1a and b) . Importantly, the leading cause of treatment failure among C2/2 patients undergoing PBSCT was relapse of the underlying disease, reaching a cumulative incidence of 56% at 4 years ( Figure 1c) . In contrast, the causes of NRM in C2/2 PBSCT recipients were common HSCT complications with expected frequencies: infection associated with steroid-dependent GVHD (n ¼ 4), infection without GVHD (n ¼ 1) or GVHD without infection (n ¼ 3). Neither HLA-C KIR ligand status nor graft source was significantly associated with an increased risk for aGVHD grade II-IV (data not shown). Thus, the dismal outcome of C2 homozygous PBSCT recipients was mainly attributable to a high relapse incidence.
To exclude confounding effects of ATG, the analysis of C2/2 recipients was next restricted to those undergoing non-ATG-based transplants (Figure 2a) . Still, BMT resulted in a higher PFS P than PBSCT. The PFS advantage for BMT remained highly significant in the multivariate Cox model (Figure 2a) .
To generate even more homogeneous populations, the analysis of C2/2 recipients was next restricted to HLAmatched sibling transplantation (n ¼ 41). Although the resulting groups still remained unbalanced with regard to age, disease risk and conditioning type (Table 1) , BMT resulted in better PFS compared with PBSCT not only in the univariate comparison, but also in the multivariate Cox model adjusting for the above confounders (Figure 2b ). Superior PFS in BMT recipients was due to a lower relapse incidence (0.17 (95% confidence interval (CI), 0.07-0.41) vs 0.76 (95% CI, 0.59-1.00); P ¼ 0.0001; multivariate Cox RR for BMT, 0.13; P ¼ 0.007).
Next, we addressed whether a particular disease group among C2/2 recipients did benefit from BMT. In C2/2 recipients with lymphoid malignancies (n ¼ 22), the PFS advantage for BMT over PBSCT was most distinct (Figures 2c). In C2/2 recipients with AML or myelodysplastic syndrome (n ¼ 30), an advantage for BMT in terms of PFS was NS, although the figures still tended to favor BMT (0.45 (95% CI, 0.16-0.75) vs 0.17 (95% CI, 0.00-0.43); Cox RR for BMT, 0.28; P ¼ 0.23).
In contrast to C2/2 recipients, C1/2 heterozygous recipients (n ¼ 166) had a lower relapse risk after PBSCT than after BMT (Cox RR for BMT, 2.52; P ¼ 0.04). However, this did not translate into a significant benefit for PFS or OS. Finally, the outcome of C1/1 recipients (n ¼ 148) was not significantly influenced by the graft source. Likewise, the graft source had no significant impact on OS or PFS in the entire cohort (data not shown).
Survival advantage for recipients missing Bw4 in BMT but not in PBSCT By Cox regression analysis of the BMT subgroup, recipients lacking a Bw4 epitope, thus missing a ligand for KIR3DL1 (n ¼ 32), had improved OS (Cox RR, 0.45; a Log-rank P-value remains significant after Bonferroni's correction for multiple testing, considering three independent hypotheses (that is, effect of C1/1, C1/2 and C2/2), resulting in a significance threshold of 0.05/3 ¼ 0.0166. Effects of missing KIR ligands in BMT vs PBSCT J Clausen et al P ¼ 0.01) and PFS (Cox RR, 0.56; P ¼ 0.04), compared with Bw4 positive recipients (n ¼ 86). This was mainly attributable to a lower NRM rate (Cox RR, 0.37; P ¼ 0.01). In contrast, following PBSCT, recipients missing Bw4 (n ¼ 76) had no survival benefit compared with Bw4 positive recipients (n ¼ 188; Cox RR, 1.03; P ¼ 0.88 for OS, and RR, 0.91; P ¼ 0.6 for PFS).
Marginal benefit of missing C2 or Bw4 in ATG-based transplants In ATG-based transplants (n ¼ 106), C1/1 recipients (n ¼ 40) tended to have a lower relapse risk than those with at least one C2 allele (n ¼ 66; Cox RR, 0.47; P ¼ 0.09). Additionally, missing Bw4 (n ¼ 34) was associated with a trend for better PFS (Cox RR, 0.6; P ¼ 0.06), due to a tendentially decreased relapse risk (Cox RR, 0.47; P ¼ 0.08). In contrast, following non-ATG-based transplantation, neither missing Bw4 nor missing C2 conferred an advantage to the recipient (data not shown).
Discussion
Based on our observation of an adverse impact of missing HLA-C group 1 KIR ligands in T cell replete, matched related PBSCT, we have previously hypothesized that the effects of KIR ligands in HSCT may critically depend not only on the use of TCD but also on the applied graft source. 21 By providing the first study to test this hypothesis as the primary endpoint, we show here that: (i) In accordance with the missing KIR ligand model, BMT recipients missing HLA-C or Bw4 ligands for inhibitory KIR had a favorable outcome, compared with C1/2 heterozygous or Bw4 positive recipients, respectively. (ii) Contrary to the missing KIR ligand model, missing an HLA-C KIR ligand was a significant adverse factor in the setting of PBSCT, particularly in case of missing C1, that is, C2 homozygosity. (iii) Our findings suggest that BM may be preferable to PBSC as graft source for C2 homozygous recipients with respect to PFS and OS. (iv) Finally, our data suggest that in vivo TCD by low-dose ATG may also promote a benefit of missing KIR ligands, but to a lesser extent than the more vigorous ex vivo TCD, 16, 25 and to a lesser extent than we show here for BM as graft source.
The role of missing KIR ligands in HSCT has remained controversial, as its mechanisms are as yet elusive. 19 Furthermore, a number of clinical studies aimed at reproducing the model have yielded seemingly conflicting results. 3, 5, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] 25 So far, the missing KIR ligand model has therefore been considered at best to be of predictive value without suggesting practical consequence, as it relies on the recipient's HLA type, which is evidently irrevocable. Contrasting with this consideration, the present study suggests that a significant advantage might be taken from the differential effects of missing KIR ligands in BMT vs PBSCT. In practice, this could imply that a C2 homozygous recipient might benefit if he is grafted with BM instead of PBSC. According to the present data, this seems to apply particularly to sibling and to non-ATG-based transplants (which partly overlap with the former), and to recipients with lymphoid malignancies.
A possible explanation for the role of the graft source for KIR ligand effects is based on the assumption that T cells affect the development of NK cells during the first months after HSCT. This interaction is widely considered the main cause for NK cell-or KIR-related effects to emerge preferentially after T cell-depleted HSCT. Even unmanipulated BM grafts contain only one tenth of the number of T cells present in PBSC grafts. Thus, a similar mechanism may explain the preferential emergence of KIR ligand effects in unmanipulated BMT as opposed to unmanipulated PBSCT. In addition, stem cell mobilization with G-CSF has been shown to polarize T cells towards a Th2 profile, 26 and to impair the cytotoxic and proliferative properties of NK cells. 27, 28 Therefore, not only the higher number of T cells in G-CSF-mobilized PBSC grafts, but also their altered profile may explain that NK cell effects particularly appear after T cell-depleted PBSCT, and after unmanipulated BMT, as shown here. Experimental data have recently substantiated the modulating role of T cells for KIR ligand effects in the HLA-matched setting. 19, 25 Our observation in PBSCT recipients supports the previously reported disadvantage of C2 homozygosity of the recipient. 12, 14, 21, 22 Several experimental findings may explain this common observation: (i) the binding affinity of C2 ligands to the inhibitory KIR2DL1 is stronger than that of C1 to KIR2DL2/3; (ii) C2 ligands not only have affinity to KIR2DL1 but also to some KIR2DL2 alleles; and (iii) developing NK cells sequentially express individual KIRs, with a delayed expansion of KIR2DL1 þ NK cells after HSCT. 13, [29] [30] [31] The present findings are furthermore in line with previous retrospective studies, considering the applied graft source and TCD. In fact, those studies favoring the missing KIR ligand model were largely based on BMT and/or T cell-depleted HSCT. 3, 5, [16] [17] [18] 25 On the contrary, most of the studies questioning the missing KIR ligand model were based on combined analyses of BMT and PBSCT, 12, 14, 20 or were restricted to PBSCT. 21 As an exception, Gagne et al., 22 have reported poor outcome in C2/2 recipients with myelogenous diseases following BMT. While this observation seems to contrast the present findings, the discrepancy may still be explained by the fact that Gagne's study comprised exclusively unrelated transplants, and thus probably contained a higher proportion of ATG-based transplants. As our data suggest a benefit of C2 homozygosity, particularly in non-ATG-based BMT, a higher proportion of ATG-based transplants in Gagne's study may have led to the reported unfavorable outcome of C2/2 recipients. Studies reported by Fischer 13 and Bjo¨rk-lund 19 provided separate analyses of BMT and PBSCT. Their data are indeed compatible with our hypothesis that missing KIR ligand effects depend on the graft type. However, as the above studies were not primarily designed to compare BMT to PBSCT in this regard, these secondary findings remained below statistical significance.
In conclusion, the present data suggest that the choice between BMT and PBSCT in malignant diseases should not be considered definite in general favor of PBSCT. Rather, in insufficiently defined subgroups, BMT may protect against relapse more efficiently than does PBSCT. One of these subgroups seems to be constituted by C2 homozygous recipients. In case our observation can be confirmed in larger cohorts, it will provide a novel rationale for choosing the graft source on the basis of the recipient's HLA-C KIR ligand status.
